We enable the acceleration of life science research
and development in the pursuit of improved human health
AiPharma Signs Heads of Agreement to Acquire a Controlling Interest in a Pharmaceutical Business with Global Innovation, Manufacturing, Distribution Footprint, and Revenues in Excess of $450 Million
The transaction is a strategic opportunity to position AiPharma as a fully integrated biotech innovation company
Delaware, USA – December 1st, 2021 – AiPharma Global Holdings LLC (“AiPharma” or the “Company”) has signed a Heads of Agreement with an international pharmaceutical business to acquire a controlling interest. AiPharma is a company focused on discovering, developing and commercializing antiviral therapies across a broad spectrum of infectious diseases. AiPharma holds directly, or through its affiliates, worldwide (excluding Japan) exclusive rights to Avigan (Favipiravir) a broad spectrum oral antiviral treatment that targets COVID-19 and 11 other classes of infectious diseases.
The potential acquisition presents an opportunity to accelerate AiPharma’s key innovation, operation, and commercialization goals starting in early 2022 as follows:
• Expansion to an existing portfolio of innovative molecules
• Integration of global manufacturing capabilities into current operational infrastructure
• Global distribution network offering additional channels for AiPharma’s current and future products
• Compelling financial profile, the target acquisition has diversified annual revenues in excess of $450M USD
“This proposed transaction has the potential to accelerate AiPharma’s overall business goals and its ability to develop and commercialize new molecules and drugs at a more rapid pace. We look forward to advancing this opportunity that allows us to execute on our strategy of growth, global expansion and product portfolio diversification, creating long-term value for investors and stakeholders.” stated Dr. Alessandro Gadotti, CEO AiPharma Group.
AiPharma has secured a commitment up to 650M USD from a multi-family office for the funding of this acquisition.
The acquisition and the relative funding is subject to confirmatory due diligence, entry into a definitive agreement based on agreed terms and other closing conditions, including regulatory, board and shareholder approvals.
AiPharma is a biopharmaceutical company focused on discovering, developing, and commercializing oral therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company’s deep understanding of antiviral drug development, nucleotide chemistry, biology, biochemistry, and virology, AiPharma has built a nucleotide prodrug platform to develop novel product candidates to treat
single-stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases.
Currently, AiPharma is focused on the clinical and commercial development of orally available, potent, and selective nucleotide prodrugs for
difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV). AiPharma also holds exclusive commercial rights for Avigan in Russia and China.
For more information, please visit www.aipharmalab.com.